Drug intelligence / Profile preview

NC-iMSC

Development stage: Preclinical
Lead developer: Citius Pharmaceuticals
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

NC-iMSC is an iPSC-derived mesenchymal stem cell (iMSC) therapy developed by Citius Pharmaceuticals through its subsidiary NoveCite, under an exclusive worldwide license from Novellus Therapeutics. The therapy leverages Novellus's patented mRNA-based cell reprogramming technology to generate the iMSCs. It is intended for the treatment of acute inflammatory respiratory conditions, with a primary focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. This therapy aims to overcome manufacturing and potency challenges associated with traditional donor-derived stem cells.

Other names: iPSC-derived mesenchymal stem cell therapy

Beyond the preview

Go deeper on NC-iMSC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NC-iMSC.

Explore the full profile